EE05404B1 - Kinuklidiini derivaat, selle saamine ja kasutamine ravimi valmistamiseks, mis on ette n„htud respiratoorsete, kuseelundite v?i mao-soolte haiguste ravimiseks, ning seda sisaldav ravimkompositsioon - Google Patents

Kinuklidiini derivaat, selle saamine ja kasutamine ravimi valmistamiseks, mis on ette n„htud respiratoorsete, kuseelundite v?i mao-soolte haiguste ravimiseks, ning seda sisaldav ravimkompositsioon

Info

Publication number
EE05404B1
EE05404B1 EEP200300312A EEP200300312A EE05404B1 EE 05404 B1 EE05404 B1 EE 05404B1 EE P200300312 A EEP200300312 A EE P200300312A EE P200300312 A EEP200300312 A EE P200300312A EE 05404 B1 EE05404 B1 EE 05404B1
Authority
EE
Estonia
Prior art keywords
preparation
urinary
respiratory
medicament
treatment
Prior art date
Application number
EEP200300312A
Other languages
English (en)
Estonian (et)
Inventor
Prat Quinones Maria
Dolors Fernandez Forner Maria
Antonia Buil Albero Maria
Original Assignee
Almirall Prodesfarma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall Prodesfarma Ag filed Critical Almirall Prodesfarma Ag
Publication of EE200300312A publication Critical patent/EE200300312A/xx
Publication of EE05404B1 publication Critical patent/EE05404B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EEP200300312A 2000-12-28 2001-12-20 Kinuklidiini derivaat, selle saamine ja kasutamine ravimi valmistamiseks, mis on ette n„htud respiratoorsete, kuseelundite v?i mao-soolte haiguste ravimiseks, ning seda sisaldav ravimkompositsioon EE05404B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200003130 2000-12-28
PCT/EP2001/015168 WO2002053564A2 (fr) 2000-12-28 2001-12-20 Nouveaux derives de quinuclidine et compositions medicinales contenant ces derniers

Publications (2)

Publication Number Publication Date
EE200300312A EE200300312A (et) 2003-10-15
EE05404B1 true EE05404B1 (et) 2011-04-15

Family

ID=8496180

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300312A EE05404B1 (et) 2000-12-28 2001-12-20 Kinuklidiini derivaat, selle saamine ja kasutamine ravimi valmistamiseks, mis on ette n„htud respiratoorsete, kuseelundite v?i mao-soolte haiguste ravimiseks, ning seda sisaldav ravimkompositsioon

Country Status (33)

Country Link
US (4) US7122558B2 (fr)
EP (1) EP1353919B1 (fr)
JP (1) JP4295985B2 (fr)
KR (1) KR100869721B1 (fr)
CN (1) CN1250545C (fr)
AR (1) AR032072A1 (fr)
AT (1) ATE334128T1 (fr)
AU (1) AU2002238471B2 (fr)
BG (1) BG66162B1 (fr)
BR (1) BR0116624A (fr)
CA (1) CA2433128C (fr)
CY (1) CY1105719T1 (fr)
CZ (1) CZ301209B6 (fr)
DE (1) DE60121813T2 (fr)
DK (1) DK1353919T3 (fr)
EC (1) ECSP034672A (fr)
EE (1) EE05404B1 (fr)
ES (1) ES2266291T3 (fr)
HU (1) HUP0303524A3 (fr)
IL (2) IL156558A0 (fr)
MX (1) MXPA03005862A (fr)
MY (1) MY136067A (fr)
NO (1) NO328772B1 (fr)
NZ (1) NZ526674A (fr)
PE (1) PE20020721A1 (fr)
PL (1) PL363807A1 (fr)
PT (1) PT1353919E (fr)
RU (1) RU2282629C2 (fr)
SI (1) SI1353919T1 (fr)
SK (1) SK287414B6 (fr)
UA (1) UA75626C2 (fr)
WO (1) WO2002053564A2 (fr)
ZA (1) ZA200305008B (fr)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
NZ526580A (en) 2000-12-22 2005-04-29 Almirall Prodesfarma Ag Quinuclidine carbamate derivatives and their use as M3 antagonists
DE60121813T2 (de) * 2000-12-28 2007-09-20 Almirall Ag Neue chinuclidinderivate und medizinische zusammensetzungen, die diese verbindungen enthalten
GB0118373D0 (en) * 2001-07-27 2001-09-19 Glaxo Group Ltd Novel therapeutic method
ES2203327B1 (es) 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
ES2204295B1 (es) 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
AU2002345266B2 (en) * 2002-07-08 2009-07-02 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
WO2004014363A1 (fr) * 2002-08-09 2004-02-19 Ranbaxy Laboratories Limited Derives d'azabicyclo[3.1.0] hexane 3,6-disubstitues, utiles en tant qu'agonistes de recepteurs muscariniques
TWI295669B (en) 2002-10-30 2008-04-11 Theravance Inc Substituted 4-amino-1-(pyridylmethyl) piperidine and related compounds
EP1618091A1 (fr) 2003-04-09 2006-01-25 Ranbaxy Laboratories, Ltd. Derives d'azabicyclo hexane substitues en tant qu'antagonistes de recepteurs muscariniques
JP2006522787A (ja) 2003-04-11 2006-10-05 ランバクシー ラボラトリーズ リミテッド ムスカリン様受容体アンタゴニストとしてのアザビシクロ誘導体
CN100445281C (zh) * 2003-05-02 2008-12-24 诺瓦提斯公司 与毒蕈碱性m3受体结合的奎宁环衍生物
AR044134A1 (es) * 2003-05-02 2005-08-24 Novartis Ag Derivados de quinuclidina, metodo de preparacion y composiciones farmaceuticas.
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
DE602004021921D1 (de) 2003-05-28 2009-08-20 Theravance Inc Azabicycloalkanverbindungen als muscarinrezeptor antagonisten
WO2005007645A1 (fr) 2003-07-11 2005-01-27 Theravance, Inc. Composes de 4-amino-1-benzylpiperidine substitues
US20050026887A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a steroid
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
ES2239546B1 (es) * 2004-03-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos esteres de quinuclidina cuaternizados.
UY28871A1 (es) 2004-04-27 2005-11-30 Glaxo Group Ltd Antagonistas del receptor de acetilcolina muscarinico
EP1747219A4 (fr) * 2004-05-13 2010-05-26 Glaxo Group Ltd Domaine de l'invention antagonistes récepteurs d'acétyle choline muscarinique
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
PT1891974E (pt) * 2004-05-31 2010-09-27 Almirall Sa Combinações que compreendem agentes anti-muscarínicos e inibidores de pde4
EP1797040A1 (fr) * 2004-09-29 2007-06-20 Ranbaxy Laboratories Limited Antagonistes de recepteurs muscariniques
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
WO2006047427A1 (fr) * 2004-10-25 2006-05-04 Schering Corporation Antagonistes des recepteurs m1 et/ou m3 combines a d'autres agents actifs pour le traitement de maladies respiratoires
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
AU2006305619A1 (en) 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Pharmaceutical compositions of muscarinic receptor antagonists
WO2007045477A2 (fr) 2005-10-21 2007-04-26 Novartis Ag Molecules organiques
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
PT2322525E (pt) 2006-04-21 2013-12-26 Novartis Ag Derivados de purina para utilização como agonistas do recetor de adenosina a2a
ES2298049B1 (es) 2006-07-21 2009-10-20 Laboratorios Almirall S.A. Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
WO2008037477A1 (fr) 2006-09-29 2008-04-03 Novartis Ag PYRAZOLOPYRIMIDINES UTILISÉES COMME INHIBITEURS DES LIPIDES KINASES Pl3K
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
RS51644B (sr) 2007-01-10 2011-10-31 Irm Llc. Jedinjenja i preparati kao inhibitori kanal aktivirajuće proteaze
EP2119716A4 (fr) 2007-02-09 2011-06-01 Astellas Pharma Inc Composé à cycle à pont aza
EP2121688A1 (fr) * 2007-02-15 2009-11-25 Argenta Discovery Ltd Dérivés hétérocycliques en tant que récepteurs muscariniques m3
CN101687851B (zh) 2007-05-07 2013-02-27 诺瓦提斯公司 有机化合物
JP5656288B2 (ja) * 2007-09-07 2015-01-21 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ムスカリン受容体アンタゴニストとして有用なグアジニン含有化合物
CA2608561A1 (fr) * 2007-10-29 2009-04-29 Carl Paluszkiewicz Support d'accessoires de deflecteur pour motocyclette
CL2008003651A1 (es) 2007-12-10 2009-06-19 Novartis Ag Compuestos derivados de 3,5-diamino-6-cloropirazinamida sustituida; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de una condición inflamatoria o alergica, en particular una enfermedad inflamatoria u obstructiva de las vias respiratorias.
US8017617B2 (en) * 2007-12-14 2011-09-13 Theravance, Inc. Amidine-containing compounds useful as muscarinic receptor antagonists
AU2009203693B2 (en) 2008-01-11 2012-06-07 Novartis Ag Pyrimidines as kinase inhibitors
EP2100599A1 (fr) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Composition à inhaler comprenant aclidinium pour le traitement de l'asthme et de maladies respiratoires obstructives chroniques
EP2100598A1 (fr) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Composition à inhaler comprenant aclidinium pour le traitement de l'asthme et de maladies respiratoires obstructives chroniques
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
EA017627B1 (ru) 2008-05-13 2013-01-30 Астразенека Аб Хинуклидиновые производные в качестве антагонистов мускаринового м3 рецептора
GB0808708D0 (en) * 2008-05-13 2008-06-18 Astrazeneca Ab New compounds 274
GB0808707D0 (en) * 2008-05-13 2008-06-18 Argenta Discovery Ltd New compounds 275
CA2727196A1 (fr) 2008-06-10 2009-12-17 Novartis Ag Composes organiques
US8263623B2 (en) 2008-07-11 2012-09-11 Pfizer Inc. Triazol derivatives useful for the treatment of diseases
GB0814729D0 (en) * 2008-08-12 2008-09-17 Argenta Discovery Ltd New combination
PL2391366T3 (pl) 2009-01-29 2013-04-30 Novartis Ag Podstawione benzimidazole do leczenia gwiaździaków
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EA201200260A1 (ru) 2009-08-12 2012-09-28 Новартис Аг Гетероциклические гидразоны и их применение для лечения рака и воспаления
NZ598220A (en) 2009-08-17 2014-02-28 Intellikine Llc Heterocyclic compounds and uses thereof
CA2771432A1 (fr) 2009-08-20 2011-02-24 Novartis Ag Composes d'oximes heterocycliques
US20110098311A1 (en) 2009-10-22 2011-04-28 Vertex Pharmaceuticals Incorported Compositions for treatment of cystic fibrosis and other chronic diseases
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
EP2386555A1 (fr) 2010-05-13 2011-11-16 Almirall, S.A. Nouveaux dérivés de cyclohéxylamine dotés d'activités agoniste bêta 2 adrénergique et antagoniste muscarinique m3
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (fr) 2010-09-09 2012-03-15 Irm Llc Composés et compositions comme inhibiteurs de trk
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
EP2673277A1 (fr) 2011-02-10 2013-12-18 Novartis AG Composés de [1, 2, 4]triazolo [4, 3 -b]pyridazine en tant qu'inhibiteurs de la tyrosine kinase c-met
WO2012116237A2 (fr) 2011-02-23 2012-08-30 Intellikine, Llc Composés hétérocycliques et leurs utilisations
MA34969B1 (fr) 2011-02-25 2014-03-01 Irm Llc Composes et compositions en tant qu inibiteurs de trk
EP2510928A1 (fr) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium pour l'amélioration du sommeil des patients avec des maldadies respiratoires
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
CA2848809A1 (fr) 2011-09-15 2013-03-21 Novartis Ag 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines substituees en position 6 a activite tyrosine kinase
WO2013038373A1 (fr) 2011-09-16 2013-03-21 Novartis Ag Dérivés pyrimidinamides
WO2013038381A1 (fr) 2011-09-16 2013-03-21 Novartis Ag Dérivés d'amide pyridine/pyrazine
WO2013038378A1 (fr) 2011-09-16 2013-03-21 Novartis Ag Dérivés pyridinamides
WO2013038386A1 (fr) 2011-09-16 2013-03-21 Novartis Ag Composés hétérocycliques destinés au traitement de la mucosviscidose
ES2882807T3 (es) 2011-09-16 2021-12-02 Novartis Ag Heterociclil carboxamidas N-sustituidas
JP6130391B2 (ja) 2011-11-23 2017-05-17 インテリカイン， エルエルシー Ｍｔｏｒ阻害剤を使用する強化された治療レジメン
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
AU2013243097A1 (en) 2012-04-03 2014-10-09 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
EP2968340A4 (fr) 2013-03-15 2016-08-10 Intellikine Llc Combinaison d'inhibiteurs de kinase et ses utilisations
JP6218940B2 (ja) * 2013-07-13 2017-10-25 ベイジン エフエスウェルカム テクノロジー ディベロップメント カンパニー リミテッド キニン系化合物、その光学異性体及びその製造方法と医薬用途
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
CA2945212A1 (fr) 2014-04-24 2015-10-29 Novartis Ag Derives amines de pyrazine utilisables en tant qu'inhibiteurs de la phosphatidylinositol 3-kinase
US9862711B2 (en) 2014-04-24 2018-01-09 Novartis Ag Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
BR112016024484A2 (pt) 2014-04-24 2017-08-15 Novartis Ag derivados de aminopiridina como inibidores de fosfatidilinositol 3-quinase
WO2016011658A1 (fr) 2014-07-25 2016-01-28 Novartis Ag Polythérapie
CA2954862A1 (fr) 2014-07-31 2016-02-04 Novartis Ag Polytherapie
AU2020290094B2 (en) 2019-06-10 2024-01-18 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF, COPD, and bronchiectasis
AU2020338971B2 (en) 2019-08-28 2023-11-23 Novartis Ag Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4465834A (en) 1965-09-20 1984-08-14 Fmc Corporation Anticholinergic drugs
GB1219606A (en) 1968-07-15 1971-01-20 Rech S Et D Applic Scient Soge Quinuclidinol derivatives and preparation thereof
US4082756A (en) * 1971-04-16 1978-04-04 Colgate-Palmolive Company Quaternary quinuclidinium carbamates and thiocarbamates
US4431627A (en) * 1980-06-03 1984-02-14 Research Corporation Gamma-emitting receptor-binding 3-quinuclidinyl glycolates; methods of preparation thereof and imaging and assay methods utilizing same
EP0052645B1 (fr) * 1980-06-03 1987-05-13 Research Corporation Benzylates de quinuclindinyle a emission de rayon gamma et de liaison de recepteurs leurs procedes de preparation et procedes de mise en image et d'essai les utilisant
FR2539135B1 (fr) 1983-01-11 1986-02-28 Essilor Int Hydrogels de polyurethane et procede de fabrication
IL72788A (en) * 1984-08-28 1989-07-31 Israel State Bis quaternary oxy-bis methylene(or trimethylene)bis-n-quinuclidines,pyridines and piperidines,their preparation and antidotes against organophosphorus and carbamate poisoning containing them
US4644003A (en) * 1985-04-03 1987-02-17 Research Corporation 3-quinuclidinol esters, useful as antagonists of muscarinic acetylcholine receptors
US4675326A (en) * 1985-05-08 1987-06-23 Gabriel Amitai Bisquaternary antidotes
US4843074A (en) 1988-05-17 1989-06-27 Marion Laboratories, Inc. 1-azabicyclo[2.2.2]octan-3-yl 2-aryl-3-azacyclo-2-hydroxypropionates and their quaternary salts
IT1230881B (it) * 1989-06-20 1991-11-08 Angeli Inst Spa Derivati del r(-) 3-chinuclidinolo
DE3931041C2 (de) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
GB8923590D0 (en) 1989-10-19 1989-12-06 Pfizer Ltd Antimuscarinic bronchodilators
EP0500864B1 (fr) * 1990-09-06 2001-09-19 Pfizer Limited Bronchodilatateurs antimuscariniques
DE4108393A1 (de) 1991-03-15 1992-09-17 Boehringer Ingelheim Kg Neue ester bi- und tricyclischer aminoalkohole, ihre herstellung und ihre verwendung in arzneimitteln
GB9119705D0 (en) 1991-09-14 1991-10-30 Pfizer Ltd Therapeutic compounds
AU685225B2 (en) 1994-02-10 1998-01-15 Yamanouchi Pharmaceutical Co., Ltd. Novel carbamate derivative and medicinal composition containing the same
NO2005012I1 (no) 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
ATE205490T1 (de) * 1995-10-13 2001-09-15 Banyu Pharma Co Ltd Substituierte heteroaromatische derivate
PE92198A1 (es) * 1996-08-01 1999-01-09 Banyu Pharma Co Ltd Derivados de 1,4-piperidina disustituida que contienen fluor
US7214687B2 (en) * 1999-07-14 2007-05-08 Almirall Ag Quinuclidine derivatives and medicinal compositions containing the same
ES2165768B1 (es) * 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
KR100751981B1 (ko) 2000-06-27 2007-08-28 라보라토리오스 살바트, 에스.에이. 아릴알킬아민으로부터 유도된 카바메이트
NZ526580A (en) * 2000-12-22 2005-04-29 Almirall Prodesfarma Ag Quinuclidine carbamate derivatives and their use as M3 antagonists
DE60121813T2 (de) * 2000-12-28 2007-09-20 Almirall Ag Neue chinuclidinderivate und medizinische zusammensetzungen, die diese verbindungen enthalten

Also Published As

Publication number Publication date
CZ20031812A3 (en) 2004-05-12
SK287414B6 (sk) 2010-09-07
US20100234332A1 (en) 2010-09-16
BG107950A (bg) 2004-03-31
PE20020721A1 (es) 2002-10-01
UA75626C2 (en) 2006-05-15
US7893087B2 (en) 2011-02-22
IL156558A (en) 2009-06-15
KR100869721B1 (ko) 2008-11-21
CZ301209B6 (cs) 2009-12-09
EE200300312A (et) 2003-10-15
PL363807A1 (en) 2004-11-29
SK7992003A3 (en) 2004-08-03
ES2266291T3 (es) 2007-03-01
ATE334128T1 (de) 2006-08-15
CY1105719T1 (el) 2010-12-22
DK1353919T3 (da) 2006-11-20
DE60121813T2 (de) 2007-09-20
MXPA03005862A (es) 2005-09-08
PT1353919E (pt) 2006-11-30
WO2002053564A2 (fr) 2002-07-11
HK1055739A1 (en) 2004-01-21
KR20030067726A (ko) 2003-08-14
NO20033002D0 (no) 2003-06-30
RU2003123120A (ru) 2005-01-10
MY136067A (en) 2008-08-29
DE60121813D1 (de) 2006-09-07
HUP0303524A2 (hu) 2004-01-28
CN1250545C (zh) 2006-04-12
BR0116624A (pt) 2003-12-23
JP2004517123A (ja) 2004-06-10
EP1353919B1 (fr) 2006-07-26
JP4295985B2 (ja) 2009-07-15
NO20033002L (no) 2003-06-30
US20040072863A1 (en) 2004-04-15
WO2002053564A3 (fr) 2002-10-31
AU2002238471B2 (en) 2007-06-28
HUP0303524A3 (en) 2008-03-28
CN1487938A (zh) 2004-04-07
IL156558A0 (en) 2004-01-04
US20070105897A1 (en) 2007-05-10
RU2282629C2 (ru) 2006-08-27
EP1353919A2 (fr) 2003-10-22
US20070129398A1 (en) 2007-06-07
NZ526674A (en) 2005-03-24
BG66162B1 (bg) 2011-09-30
CA2433128C (fr) 2010-05-25
NO328772B1 (no) 2010-05-10
AR032072A1 (es) 2003-10-22
ZA200305008B (en) 2005-01-26
SI1353919T1 (sl) 2006-12-31
CA2433128A1 (fr) 2002-07-11
ECSP034672A (es) 2003-08-29
US7879874B2 (en) 2011-02-01
US7122558B2 (en) 2006-10-17

Similar Documents

Publication Publication Date Title
EE05404B1 (et) Kinuklidiini derivaat, selle saamine ja kasutamine ravimi valmistamiseks, mis on ette n„htud respiratoorsete, kuseelundite v?i mao-soolte haiguste ravimiseks, ning seda sisaldav ravimkompositsioon
EE200300295A (et) Kinuklidiinkarbamaadi derivaat, selle saamine ja kasutamine ravimi valmistamiseks, mis on ette nähtud respiratoorsete, kuseelundite või mao-soolte haiguste ravimiseks, ning seda sisaldav ravimkompositsioon
EE05180B1 (et) Asaindooli sisaldav farmatseutiline kompositsioon raviotstarbeliseks kasutamiseks, asaindoolid ning nende kasutamine ravimite valmistamiseks, mis on ette n„htud proteiinikinaasi kataltilise toime p„rssimiseks
EE200200046A (et) 8-fenüül-6,9-dihüdro-[1,2,4]triasolo[3,4-i]puriin-5-ooni derivaat, selle valmistamine ja raviotstarbeline kasutamine ning seda sisaldav farmatseutiline kompositsioon
EE04850B1 (et) Pürimidiini derivaatide kasutamine ravimi valmistamiseks, mis on ette nähtud HIV nakkuse raviks, ühend, seda sisaldav farmatseutiline kompositsioon, meetod ühendi ja kompositsiooni valmistamiseks ning kombineeritud preparaat kasutamiseks HIV nakku
EE04852B1 (et) C-21 modifitseeritud epotioloonid, nende valmistamise meetod ning kasutamine ja ravimkoostise kasutamine vähkkasvajate või teiste proliferatiivsete haiguste ravimisel
EE200200274A (et) Pürrolidiinatseetamiidi derivaadi kasutamine ravimi valmistamiseks, mis on ette nähtud kesknärvisüsteemi häirete ravimiseks, ja farmatseutiline kompositsioon
TWI340640B (en) Combination, kit and pharmaceutical composition for treatment of parkinson's disease
EE04175B1 (et) Meetod topiramaadi farmatseutilise kompositsioonivalmistamiseks, farmatseutiline kompositsioon ning topiramaadi kasutamine diabeedi raviks ette nähtud ravimi valmistamiseks
IL222495A (en) Use of an isolated human antibody tnfa antibody to create a drug for the treatment of idiopathic inflammatory bowel disease, a pharmaceutical product, kit and pre-loaded syringe containing it
DE60126923D1 (de) Therapeutische zusammensetzungen bestehend aus antihypotensiva und antiangiogenika
IL178822A (en) 4-phenylamino-quinazolin-6-yl-amides, pharmaceutical compositions comprising the same and use thereof in the preparation of medicaments for the treatment of proliferative disorders
HUP0204574A3 (en) Propionic acid derivatives and their use in the treatment of diabetes and obesity, pharmaceutical compositions containing them and their preparation
EE04493B1 (et) Tsüklopenteeni derivaadid, neid sisaldav farmatseutiline kompositsioon ning ühendite kasutamine ravimina inimestel esinevate motiliini retseptoriga seotud häirete raviks
EE200200199A (et) N-guanidinoalküülamiid, meetod selle valmistamiseks, seda sisaldav farmatseutiline preparaat ning raviotstarbeline kasutamine
EE200300398A (et) Isoksasoliini derivaat, selle saamine ja kasutamine depresioonivastase ravimi valmistamiseks ning seda sisaldav ravimkompositsioon
EE200300139A (et) Kemokiini mutandi kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on ette nähtud hulgiskleroosi ja teiste müeliinikaotusega seotud haiguste raviks
CA2436511A1 (fr) Utilisation de flumazenil dans l'elaboration d'un medicament destine au traitement de la dependance a la cocaine
EE200100689A (et) IL6RIL6 kimääri kasutamine ravimi valmistamiseks,mis on ette nähtud neuroloogiliste haiguste ravimiseks, ning farmatseutiline kompositsioon
TWI347845B (en) Pharmaceutical compositions,combinations,and kits for the treatment of respiratory diseases and use of the same
HUP0204391A3 (en) The use of mirtazapine for the preparation of pharmaceutical composition suitable for the treatment of sleep disorders
EE200200480A (et) Memnopeptiidühend, selle valmistamine ja raviotstarbeline kasutamine ning seda sisaldav farmatseutiline kompositsioon
EE200200260A (et) Pürasolo[1,5-d][1,2,4]triasiinderivaat, selle saamine ja kasutamine ravimi valmistamiseks, mis on ette nähtud kognitsiooni suurendamiseks, ning seda sisaldav farmatseutiline kompositsioon
EE200300184A (et) Farmatseutiline kompositsioon, mis sisaldab kamptotetsiini kombinatsioonis stilbeeni derivaadiga, ning selle kasutamine vähktõve raviks
EE04941B1 (et) Ravimid skisofreenia ennetamiseks ja raviks ning nende valmistamine

Legal Events

Date Code Title Description
HC1A Change of owner name
GB1A Change in the ownership or in the address of the owner
MM4A Lapsed by not paying the annual fees

Effective date: 20111220